Physician profile
Michael Batalo
NPI 1750525838
$670.07
in general payments reported to CMS, 2019-2025
14 companies · $55.07 in 2025
The $55.07 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $87.18 · 2021: $11.13 · 2022: $33.42 · 2023: $38.20 · 2025: $55.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.62 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.62 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $126.79 | 2019-2020 | |
| Lilly USA, LLC | $112.91 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $100.64 | 2019-2023 | Calquence |
| Pfizer INC. | $68.36 | 2019-2025 | |
| Celgene Corporation | $42.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.27 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.32 | 2019-2020 | |
| Daiichi Sankyo INC. | $30.94 | 2019 | |
| Medtronic, INC. | $28.15 | 2021-2022 | |
| Iovance Biotherapeutics, INC. | $24.42 | 2025 | Amtagvi |
| Novartis Pharmaceuticals Corporation | $16.40 | 2022 | |
| Amgen INC. | $13.22 | 2023 | Lumakras |
| Janssen Biotech, INC. | $12.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Batalo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.